# GlycanAge

> GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.

- **Founded:** 2020
- **Headquarters:** Newcastle upon Tyne, United Kingdom
- **Founders:** Nikolina Lauc (Co-Founder & CEO), Gordan Lauc (Co-Founder & Chief Scientific Officer), Filip Lauc (Co-Founder & CTO)
- **Team size:** ~53 employees
- **Products:** GlycanAge Test, Specialist Consultation, Subscription & Retest Plans, Clinical / Lab-Developed Tests (LDTs)
- **Notable:** Commercialized ~20 years of glycobiology research supported by roughly $40M in European grant funding, Built one of the largest proprietary datasets of the human glycome, Raised a combined ~$8.7M+ across seed and Series A rounds

## Products & services

- **GlycanAge Test** — An at-home biological age test using a finger-prick blood sample (four drops). It analyzes IgG glycans on immune cells to estimate how fast a person is aging and produces a personalized report with a glycan profile.
- **Specialist Consultation** — Every test includes a one-to-one consultation call with a longevity specialist to interpret results and guide lifestyle interventions.
- **Subscription & Retest Plans** — Annual, bi-annual, one-off and two-test bundle options so customers can track how lifestyle changes shift their biological age over time. HSA/FSA eligible.
- **Clinical / Lab-Developed Tests (LDTs)** — Glycan tests being developed for hospital deployment across stress and resilience, cardiometabolic health, weight management and hormonal health.

## Achievements

- Commercialized ~20 years of glycobiology research supported by roughly $40M in European grant funding
- Built one of the largest proprietary datasets of the human glycome
- Raised a combined ~$8.7M+ across seed and Series A rounds
- Established hospital pilots and a Saudi lab partnership to move glycan testing into clinical care
- Grew to a team of about 53 with medical and scientific advisory boards including Prof Tim Spector and Prof Andrea Maier

## Latest updates

- **2025-12** — Reported a $8.7M (approx. €7.4M) funding round led by Fifth Quarter Ventures to bring glycan-based aging diagnostics into mainstream healthcare and hospitals.
- **2025-12** — Announced plans to deploy technology in 10+ European and Middle Eastern hospitals within a year and to build clinical lab-developed tests.
- **2024-02** — Closed a $4.2M (approx. €3.9M) seed round led by LAUNCHub Ventures and Kadmos Capital to advance personalized preventative care.

## Links

- Website: https://glycanage.com
- LinkedIn: https://www.linkedin.com/company/glycanage-ltd
- Twitter/X: https://twitter.com/glycanage
- YouTube: https://www.youtube.com/@GlycanAge
- Instagram: https://www.instagram.com/glycanage/
- Facebook: https://www.facebook.com/glycanage/

---

Profile page: https://yespress.io/glycanage
Published by YesPress — https://yespress.io
Last updated: 2026-07-21